Olivier Pasquier Joins Cytoo as Chief Commercial Officer

Olivier Pasquier Joins Cytoo as Chief Commercial Officer

Grenoble, France, 18th March 2013 – CYTOO, a life science systems & tools company providing disruptive solutions for cell-based assays and High Content Screening (HCS), is delighted to announce that Olivier Pasquier has joined the team as Chief Commercial Officer.

Olivier Pasquier first graduated from the French University Nice-Sophia Antipolis in molecular biology. He then completed his background with a marketing MBA from ESCP Europe.

Former Senior Marketing Manager Europe at QIAGEN, with more than 10 years experience in biology and biotechnology, he is passionate about biotech breakthroughs. He joins the team to lead the commercial success of CYTOO's 2D+ Cell Culture Platform and develop new markets in cell based assays and screening.

François Chatelain, CEO of CYTOO, says "We're delighted to welcome Olivier at CYTOO: I have no doubt that his insights, energy and business initiatives will be really impactful on CYTOO's development!"

"It is an honour for me to join the executive team of CYTOO", says Olivier Pasquier. "This company has a unique talented team, a breakthrough technology, a secured financial background, able to deeply change the game in the cell-based assay science. I want to make sure that every lab using cell culture in the world accesses micropatterns and scientific expertise available at CYTOO."

See Olivier Pasquier's Linkedin profile

About CYTOO S.A.

CYTOO is a distinctive life sciences systems & tools company offering disruptive solutions for cell-based assays and High Content Screening (HCS) that reinforce robustness, sensitivity and powerful quantification. The Company's 2D+ Cell Culture Platform and Custom Solutions are based on adhesive micropatterns, offering control over the cells' microenvironment, leading to normalized cell morphology and behavior. The technology allows the optimization or resurrection of complex or difficult cell-based assays and enables innovative assay development.

For more information about the complete product portfolio, visit www.cytoo.com